Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 11/20 | 0.36 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654901 | 0.96 | CAPN1 (0.39) | CAPN1CTSSCTSKBCHEACHE | |
| SCHEMBL3661274 | 0.85 | HDAC8 (0.42) | CAPN1BCHEACHEHDAC8HPGD | |
| SCHEMBL3661271 | 0.85 | HDAC8 (0.42) | CAPN1BCHEACHEHDAC8HPGD | |
| SCHEMBL20355987 | 0.82 | CTSK (0.42) | CTSSCTSKHTTHDAC1HDAC4 | |
| SCHEMBL18226807 | 0.81 | CTSS (0.40) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL18226806 | 0.81 | CTSS (0.40) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL3661064 | 0.81 | CAPN1 (0.51) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL13265369 | 0.79 | CYP1A2 (0.40) | CTSSCTSKBCHEACHEHTT | |
| SCHEMBL3749003 | 0.79 | CYP1A2 (0.40) | CTSSCTSKBCHEACHEHTT | |
| SCHEMBL22688030 | 0.79 | HPGD (0.36) | CAPN1CTSSCTSKBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710000-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-04-29 | — | — | US | disclosed |
| US-20100279931-A1 | Insulin Derivative | NOVO NORDISK A/S | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279931-A1 | Insulin Derivative | IAPP, INSR, GPR119 | CAPN1 3586/4885CTSS 4077/4885CTSK 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.